Matches in DBpedia 2016-04 for { <http://dbpedia.org/resource/CDP323> ?p ?o }
Showing triples 1 to 57 of
57
with 100 triples per page.
- CDP323 abstract "CDP323 is a small-molecule prodrug antagonist of the vascular cell adhesion molecule 1 (VCAM-1) binding to α4-integrins. It was originally developed by the British biopharmaceutical company Celltech plc. (now UCB S.A.) and was a putative new drug for oral treatment of multiple sclerosis.In October 2006, UCB and Biogen Idec announced a collaboration to jointly develop and commercialize CDP323 for the treatment of multiple sclerosis and other potential indications. In June 2009, development of CDP323 was discontinued due to discouraging results of a Phase II clinical trial.".
- CDP323 wikiPageExternalLink intervention=CDP323.
- CDP323 wikiPageID "13219252".
- CDP323 wikiPageLength "4529".
- CDP323 wikiPageOutDegree "37".
- CDP323 wikiPageRevisionID "544960763".
- CDP323 wikiPageWikiLink Adverse_event.
- CDP323 wikiPageWikiLink Biogen.
- CDP323 wikiPageWikiLink Blood_vessel.
- CDP323 wikiPageWikiLink Brain.
- CDP323 wikiPageWikiLink Category:Immunosuppressants.
- CDP323 wikiPageWikiLink Celltech.
- CDP323 wikiPageWikiLink Clinical_trial.
- CDP323 wikiPageWikiLink Consecutive.
- CDP323 wikiPageWikiLink Disease.
- CDP323 wikiPageWikiLink Europe.
- CDP323 wikiPageWikiLink Experimental_autoimmune_encephalomyelitis.
- CDP323 wikiPageWikiLink Indication_(medicine).
- CDP323 wikiPageWikiLink Inflammation.
- CDP323 wikiPageWikiLink Integrin.
- CDP323 wikiPageWikiLink Interferon_type_I.
- CDP323 wikiPageWikiLink Investigational_New_Drug.
- CDP323 wikiPageWikiLink Mechanism_of_action.
- CDP323 wikiPageWikiLink Monoclonal_antibody.
- CDP323 wikiPageWikiLink Mouse.
- CDP323 wikiPageWikiLink Mouth.
- CDP323 wikiPageWikiLink Multiple_sclerosis.
- CDP323 wikiPageWikiLink Natalizumab.
- CDP323 wikiPageWikiLink Pharmacokinetics.
- CDP323 wikiPageWikiLink Placebo.
- CDP323 wikiPageWikiLink Preventive_healthcare.
- CDP323 wikiPageWikiLink Prodrug.
- CDP323 wikiPageWikiLink Reaction_inhibitor.
- CDP323 wikiPageWikiLink Receptor_antagonist.
- CDP323 wikiPageWikiLink Therapy.
- CDP323 wikiPageWikiLink Tissue_(biology).
- CDP323 wikiPageWikiLink Tolerability.
- CDP323 wikiPageWikiLink UCB_(company).
- CDP323 wikiPageWikiLink United_Kingdom.
- CDP323 wikiPageWikiLink United_States.
- CDP323 wikiPageWikiLink VCAM-1.
- CDP323 wikiPageWikiLink White_blood_cell.
- CDP323 wikiPageWikiLinkText "CDP323".
- CDP323 subject Category:Immunosuppressants.
- CDP323 hypernym Antagonist.
- CDP323 type Drug.
- CDP323 type Drug.
- CDP323 type Immunosuppressant.
- CDP323 comment "CDP323 is a small-molecule prodrug antagonist of the vascular cell adhesion molecule 1 (VCAM-1) binding to α4-integrins. It was originally developed by the British biopharmaceutical company Celltech plc. (now UCB S.A.) and was a putative new drug for oral treatment of multiple sclerosis.In October 2006, UCB and Biogen Idec announced a collaboration to jointly develop and commercialize CDP323 for the treatment of multiple sclerosis and other potential indications.".
- CDP323 label "CDP323".
- CDP323 sameAs Q166806.
- CDP323 sameAs Zaurategrast.
- CDP323 sameAs CDP323.
- CDP323 sameAs m.03bz84x.
- CDP323 sameAs Q166806.
- CDP323 wasDerivedFrom CDP323?oldid=544960763.
- CDP323 isPrimaryTopicOf CDP323.